PlumX Metrics
Embed PlumX Metrics

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Haematologica, ISSN: 1592-8721, Vol: 105, Issue: 1, Page: E26-E28
2020
  • 18
    Citations
  • 0
    Usage
  • 29
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

Introduction Historically recognized as a model for research advances regarding pathogenesis, cytogenetics and molecular genetics, as well as the first intensely chemo-sensitive tumor to be

Letter Description

Haematologica

Bibliographic Details

Strati, Paolo; Nastoupil, Loretta J; Davis, Richard E; Fayad, Luis E; Fowler, Nathan; Hagemeister, Fredrick B; Kwak, Larry; Oki, Yasuhiro; Wang, Michael; Westin, Jason; Ruben, Charnelle E; Wesson, Emily T; Piekarz, Richard; Fanale, Michelle A; Lee, Hun Ju

Ferrata Storti Foundation (Haematologica)

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know